Rupert Bauersachs1,2, Agnes Y Y Lee3, Pieter W Kamphuisen4, Guy Meyer5, Mette S Janas6, Mikala F Jarner6, Alok A Khorana7. 1. Department of Vascular Medicine, Klinikum Darmstadt GmbH, Darmstadt, Germany. 2. Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany. 3. Division of Hematology, University of British Columbia and British Columbia Cancer Agency, Vancouver, Canada. 4. Department of Internal Medicine, Tergooi, Hilversum, and Vascular Medicine, University Medical Center Groningen, Groningen, The Netherlands. 5. Respiratory Unit, Hospital European Georges Pompidou, Assistance Publique-Hopitaux de Paris, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 6. LEO Pharma, Ballerup, Denmark. 7. Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, United States.
Abstract
OBJECTIVE: This article assesses the impact of renal impairment (RI) on the efficacy and safety of anticoagulation in patients with cancer-associated thrombosis from the Comparison of Acute Treatments in Cancer Hemostasis (CATCH) study (NCT01130025). MATERIALS AND METHODS:Renal function was assessed using the Modification of Diet in Renal Disease equation in patients with cancer-associated thrombosis who received eithertinzaparin (175 IU/kg) once daily or warfarin for 6 months, in an open-label, randomized, multi-centre trial with blinded adjudication of outcomes. Associations between baseline RI (glomerular filtration rate [GFR] <60 mL/min/1.73m2) and recurrent symptomatic or incidental venous thromboembolism (VTE), clinically relevant bleeding (CRB), major bleeding and death were assessed using Fisher's exact test. RESULTS: Baseline-centralized GFR data were available for 864 patients (96% of study population). RI was found in 131 patients (15%; n = 69 tinzaparin). Recurrent VTE occurred in 14% of patients with and 8% of patients without RI (relative risk [RR] 1.74; 95% confidence interval [CI] 1.06, 2.85), CRB in 19% and 14%, respectively (RR 1.33; 95% CI 0.90, 1.98), major bleeding in 6.1% and 2.0%, respectively (RR 2.98; 95% CI 1.29, 6.90) and mortality rate was 40% and 34%, respectively (RR 1.20; 95% CI 0.94, 1.53). Patients with RI on tinzaparin showed no difference in recurrent VTE, CRB, major bleeding or mortality rates versus those on warfarin. CONCLUSION: RI in patients with cancer-associated thrombosis on anticoagulation was associated with a statistically significant increase in recurrent VTE and major bleeding, but no significant increase in CRB or mortality. No differences were observed between long-term tinzaparin therapy and warfarin. Schattauer GmbH Stuttgart.
RCT Entities:
OBJECTIVE: This article assesses the impact of renal impairment (RI) on the efficacy and safety of anticoagulation in patients with cancer-associated thrombosis from the Comparison of Acute Treatments in Cancer Hemostasis (CATCH) study (NCT01130025). MATERIALS AND METHODS: Renal function was assessed using the Modification of Diet in Renal Disease equation in patients with cancer-associated thrombosis who received either tinzaparin (175 IU/kg) once daily or warfarin for 6 months, in an open-label, randomized, multi-centre trial with blinded adjudication of outcomes. Associations between baseline RI (glomerular filtration rate [GFR] <60 mL/min/1.73m2) and recurrent symptomatic or incidental venous thromboembolism (VTE), clinically relevant bleeding (CRB), major bleeding and death were assessed using Fisher's exact test. RESULTS: Baseline-centralized GFR data were available for 864 patients (96% of study population). RI was found in 131 patients (15%; n = 69 tinzaparin). Recurrent VTE occurred in 14% of patients with and 8% of patients without RI (relative risk [RR] 1.74; 95% confidence interval [CI] 1.06, 2.85), CRB in 19% and 14%, respectively (RR 1.33; 95% CI 0.90, 1.98), major bleeding in 6.1% and 2.0%, respectively (RR 2.98; 95% CI 1.29, 6.90) and mortality rate was 40% and 34%, respectively (RR 1.20; 95% CI 0.94, 1.53). Patients with RI on tinzaparin showed no difference in recurrent VTE, CRB, major bleeding or mortality rates versus those on warfarin. CONCLUSION: RI in patients with cancer-associated thrombosis on anticoagulation was associated with a statistically significant increase in recurrent VTE and major bleeding, but no significant increase in CRB or mortality. No differences were observed between long-term tinzaparin therapy and warfarin. Schattauer GmbH Stuttgart.
Authors: M Carrier; N Blais; M Crowther; P Kavan; G Le Gal; O Moodley; S Shivakumar; V Tagalakis; C Wu; A Y Y Lee Journal: Curr Oncol Date: 2018-10-31 Impact factor: 3.677
Authors: Lara A Kahale; Maram B Hakoum; Ibrahim G Tsolakian; Charbel F Matar; Irene Terrenato; Francesca Sperati; Maddalena Barba; Victor Ed Yosuico; Holger Schünemann; Elie A Akl Journal: Cochrane Database Syst Rev Date: 2018-06-19
Authors: Mercedes Salgado; Elena Brozos-Vázquez; Begoña Campos; Paula González-Villarroel; María Eva Pérez; María Lidia Vázquez-Tuñas; David Arias Journal: Clin Appl Thromb Hemost Date: 2022 Jan-Dec Impact factor: 3.512